Secondary market valuation surged 344% following FDA breakthrough designations for vision and hearing devices.

Highlighted as a key player in hardware that actively modifies the nervous system, despite its invasive nature.

Positioned as the 'final frontier' in BCI and considered the closest to a consumer device in this advanced category, with successful patient trials.